Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 TRVI | Healthcare | $13.65 | 1.10M | $1.94B | -35.20 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TRVI | Trevi Therapeutics | 13.65 | 2.28 | 20.05% |
| Name | Price | % Change | |
|---|---|---|---|
| TRVI | $13.65 | +20.05% |
Trevi Therapeutics ($TRVI) announced an update on their ongoing clinical study. Study Overview: Trevi Therapeutics is recruiting patients for “A Randomized, Double-Blind, Placebo-Controlled Twelve-Week Fixed-Dose Study to Evaluate the Efficacy
“This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials,” said Jennifer Good, President and CEO
Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Trevi Therapeutics, retaining the price target of $28.00. Debanjana Chatterjee’s rating is based on several factors, including Trevi’s progress across
Trevi Therapeutics (TRVI) is scheduled to report 3rd quarter earnings on 11/09/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Trevi Therapeutics to post earnings of -$0.13
The F/m Emerald Life Sciences Innovation ETF (LFSC) ranks in the 12th percentile of Morningstar’s US Fund Health category, measured against 154 funds over the trailing one-year period as of
Meeting to be held in Zurich on September 30 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’
Jones raised the firm’s price target on Trevi Therapeutics (TRVI) to $28 from $24 and keeps a Buy rating on the shares following the Q2 report. The company’s late-stage execution
In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Trevi Therapeutics, with a price target of $28.00. Debanjana Chatterjee has given his Buy rating due
Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on Trevi Therapeutics and keeping the price target at $24.00. Brandon Folkes has given his Buy rating due to a
Needham analyst Serge Belanger maintained a Buy rating on Trevi Therapeutics today and set a price target of $23.00. Serge Belanger has given his Buy rating due to a combination
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| TRVI | buy | Reiterated | Nov 10, 2026 | |||
| TRVI | buy | Reiterated | Nov 10, 2026 | |||
| TRVI | buy | Reiterated | Nov 10, 2026 | |||
| TRVI | buy | Assigned | Nov 10, 2026 | |||
| TRVI | buy | Reiterated | Nov 10, 2026 | |||
| TRVI | buy | Reiterated | Nov 10, 2026 | |||
| TRVI | buy | Reiterated | Nov 9, 2026 | |||
| TRVI | buy | Reiterated | Aug 7, 2026 | |||
| TRVI | buy | Initiated | Aug 7, 2026 | |||
| TRVI | buy | Reiterated | May 7, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| TRVI | Mar 23, 2027TBA | $1.94B | $-0.15 | $0.00 | 1.13 | -35.20 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
